Pharmacokinetics

Pegylated Interferon-alpha Therapy Profiled for Chronic Hepatitis C Patients

Published in Hepatitis Weekly, January 29th, 2001

- by Sonia Bell-Nichols, staff medical writer -- Pegylated interferon-alpha 2b, when taken once a week, demonstrates the same efficacy as thrice-weekly doses of non-pegylated interferon-alpha 2b, a common treatment for patients with chronic hepatitis C, study results indicate.

Tests comparing the two drugs were conducted by Schering Plough Corporation researchers and reported in Clinical Pharmacology and Therapeutics.

"Fifty-eight patients (38 men, 20 women; age range, 25 to 65 years) with compensated chronic hepatitis C were enrolled in this open-label, randomized, active controlled study," said P. Glue and colleagues at the pharmaceutical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry